Nasdaq apls.
NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …
Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ...Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …APLS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Apellis Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.
MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...
Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Over the past 3 months, 21 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with ...
Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value.Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information. Instantly APLS has showed a red trend with a performance of -2.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 50.19 on Tuesday, 11/28/23 increased the stock’s daily price by 6.04%.NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) concerning potential …The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...
Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates ...
Find the latest Institutional Holdings data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS PR Newswire - Fri Sep 29, 3:28PM CDT /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS). Such...Fintel reports that on May 8, 2023, Citigroup maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation.. Analyst Price Forecast Suggests 4.25% Downside. As of April ...
(APLS) Share Price. NASDAQ. $49.10. As on 17-Nov-2023 16:00 EST. up-down-arrow $1.21 • 2.53%. Prev Close info. $47.89. Day's Open info. $47.74. Today's High ...Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ... 2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months.See historical performance and comparison. View Valuation. Research Apellis Pharmaceuticals' (Nasdaq:APLS) stock price, latest news & stock analysis. Find …value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) andCRESTWOOD, Ky. and WALTHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...
Nov 2, 2023 · Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ... Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ... Fintel reports that on April 14, 2023, Goldman Sachs maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 9.95% UpsideRost-9D/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Swedish Orphan Biovitrum ((Sobi)) announce that the CHMP of the EMA has adopted a positive opinion recommending the ...Fintel reports that on April 14, 2023, Goldman Sachs maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 9.95% UpsideWALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...Rost-9D/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Swedish Orphan Biovitrum ((Sobi)) announce that the CHMP of the EMA has adopted a positive opinion recommending the ...Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ...
Apr 24, 2023 · The forecasts range from a low of 51.51 to a high of $148.05. The average price target represents a decrease of 4.25% from its latest reported closing price of 93.18. See our leaderboard of ...
Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...
Follow. WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of ...With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings are expected to be released in 82 days.Apellis Pharmaceuticals (NASDAQ: APLS) · Apellis Pharmaceuticals Return vs. S&P · Apellis Pharmaceuticals Company Info · News & Analysis · Financial Health ...CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of …WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Analyst Price Forecast Suggests 203.86% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...
NEW YORK, Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging ...Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.Nov 20, 2023 · Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. Instagram:https://instagram. buy terra lunadia inverse etfvanguard gold fundbiggest real estate investment companies deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ...WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ... rare pennies 2009vanguard information technology 14 дек. 2017 г. ... More from Nasdaq. 09:11. Abivax [ABVX] Rings the. Nasdaq Closing Bell. 1 day ago · 564 views. 00:34. As home to the world's most innovative and ... day trader software Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.